May 24, 2018 06:02 PM EDTUpdated May 25, 06:13 AM

BioMarin gets its shot at another blockbuster as FDA OKs rare disease drug pegvaliase

John Carroll

Editor & Founder

BioMarin $BMRN has picked up their latest OK for their rare disease drug portfolio, with the FDA coming through with an approval on pegvaliase, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioMarin gets its shot at another blockbuster as FDA OKs rare disease drug pegvaliase

John Carroll

Editor & Founder

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

AbbVie makes another small I&I acquisition, buying Nimble for $200M

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

The key to faster, more impactful research? Put patients in the driver’s seat

Bio­Marin gets its shot at an­oth­er block­buster as FDA OKs rare dis­ease drug peg­valiase

John Carroll

Editor & Founder

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

BioMarin gets its shot at another blockbuster as FDA OKs rare disease drug pegvaliase

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

AbbVie makes another small I&I acquisition, buying Nimble for $200M

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

The key to faster, more impactful research? Put patients in the driver’s seat